Major Article - BIT225, in combination with 3-drug antiretroviral therapy, page-195

You assume that an IPO investor who still spruiks BIT after all this time has lost money?

Your argument always lacks a bit of deep thought. You talk about trading and then forget that others know how to do it.

Most, if not all, IPO investors still here would be registered sophs.

Biotron has looked after its investors by doing these things called capital raises.

Most of them have made a LOT of money from them over the years, especially the last few.

You also conveniently forget how many bags the BITOA and BITOB made for the soph CR holders (and others who saw the opportunity). An absolute fortune.